25/04/2014 01:38:03 Free Membership Login

Myriad Genetics News (NASDAQ:MYGN)

DateTimeSource
Headline
04/24/20146:00PMZACKSCan Covidien (COV) Keep the Earnings Streak Alive? - Analyst Blog
Covidien plc (COV) is set to report its second-quarter fiscal 2014 results on April 25, 2014. In the last reported quarter, the company had posted a positive earnings surprise of 6.38%. In fact, Covidien delivered positive surprises in all of its last 4 quarters, with an average beat of 2.61%. Let's see how things... More...>>
04/24/20143:00PMZACKSResMed Posts In-line Earnings but Misses on Revs - Analyst Blog
ResMed Inc.(RMD) reported third-quarter fiscal 2014 (ended Mar 31, 2014) earnings per share of 63 cents in line with the Zacks Consensus Estimate. Results, however, surpassed the prior-year quarter’s earnings of 58 cents per share, registering an increase of 8.6% year over year. Revenues in Details Revenues grew... More...>>
04/23/20141:47AMPRNUSCompany Announcements, Divestitures, Earnings Releases, and Stock Price Updates - Analyst Notes on Costco, Liberty Media, Apo...
Company Announcements, Divestitures, Earnings Releases, and Stock Price Updates - Analyst Notes on Costco, Liberty Media, Apollo Education, Yum!, and Myriad Editor Note: For more information about this release, please scroll to bottom PR Newswire NEW YORK, April 23, 2014 NEW YORK, April 23, 2014 /PRNewswire/ -- Today... More...>>
04/22/20144:05PMGLOBEMyriad Genetics to Announce Financial Results for the Third Quarter of Fiscal Year 2014 on Tuesday, May 6, 2014
SALT LAKE CITY, April 22, 2014 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced that it will issue financial results for the third fiscal quarter of 2014 following the close of market on Tuesday, May 6, 2014. The Company also will host a conference call on Tuesday, May 6, 2014 at 4:30 p.m. ET to... More...>>
04/21/20143:50PMZACKSWill Quest Diagnostics (DGX) Miss Earnings Estimates? - Analyst Blog
Quest Diagnostics Inc. (DGX) is scheduled to report its first-quarter 2014 results before the opening bell on Apr 24. Last quarter, Quest Diagnostics posted a positive earnings surprise of 9.57%. Let’s see how things are shaping up for this announcement. Factors at Play Barring the fourth quarter of 2013, Quest Diagnostics... More...>>
04/11/20149:00AMZACKSGilead Sciences (GILD) Falls: Stock Goes Down 7.3% - Tale of the Tape
Gilead Sciences Inc. (GILD) saw a big move last session, as the company’s shares fell by over 7% on the day. The move came on pretty good volume too with far more shares changing hands than in a normal session. This continues the recent downtrend for GILD, as the stock is now down almost 18% in the past one-month... More...>>
04/07/20144:30PMGLOBEMyriad Genetics Submits Premarket Approval to FDA for BRACAnalysis(R)
SALT LAKE CITY, April 7, 2014 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced that it has submitted the first module of a premarket approval (PMA) application to the Food and Drug Administration (FDA) for the use of BRACAnalysis® testing as a companion diagnostic with olaparib. Olaparib is... More...>>
04/03/20148:00AMPRNUSMarket Signal - Stocks Hitting New High -- Research on Myriad Genetics, Linear Technology, TE Connectivity, and Dover
Market Signal - Stocks Hitting New High -- Research on Myriad Genetics, Linear Technology, TE Connectivity, and Dover Editor Note: For more information about this release, please scroll to bottom. PR Newswire LONDON, April 3, 2014 LONDON, April 3, 2014 /PRNewswire/ -- The trading session on Wednesday, April 02, 2014 ended... More...>>
03/25/20147:05AMGLOBEMyriad to Present Seven Clinical Studies at the Annual Clinical Genetics Meeting
SALT LAKE CITY, March 25, 2014 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced that results from seven clinical studies will be presented at the upcoming American College of Medical Genetics (ACMG) annual meeting, which will be held Mar. 25-Mar.29, 2013 in Nashville, Tennessee. "We believe clinical... More...>>
03/24/20147:05AMGLOBEMyriad Announces HRD Companion Diagnostic Collaboration With Tesaro
SALT LAKE CITY, March 24, 2014 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced that Tesaro, Inc. will use Myriad's novel HRD (homologous recombination deficiency) test to identify tumor types that may respond to its investigational poly-ADP ribose polymerase (PARP) inhibitor, niraparib, currently... More...>>
03/20/20144:00PMGLOBEInstitut Pasteur and Myriad RBM Publish Initial Results From Landmark Study of Immune Response
PARIS and SALT LAKE CITY, March 20, 2014 (GLOBE NEWSWIRE) -- Institut Pasteur and Myriad RBM, a wholly-owned subsidiary of Myriad Genetics, Inc., today announced they have published an initial data analysis from the landmark Milieu Interieur Project in the journal Immunity, which provided new insights into the healthy... More...>>
03/20/20147:05AMGLOBESGO Updates Hereditary Cancer Recommendations
SALT LAKE CITY, March 20, 2014 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today noted that the Society of Gynecologic Oncology (SGO) has issued new clinical practice statements surrounding hereditary cancer testing for patients with ovarian and endometrial cancer. The statements are consistent with the recently... More...>>
03/12/20148:00AMPRNUSDividend, Financial Results, Publishing of Clinical Study Data, New Offerings and Conference Call Schedules - Analyst Notes o...
Dividend, Financial Results, Publishing of Clinical Study Data, New Offerings and Conference Call Schedules - Analyst Notes on H&R Block, Ulta Beauty, Myriad, QIAGEN, and Nutrisystem Editor Note: For more information about this release, please scroll to bottom. PR Newswire NEW YORK, March 12, 2014 NEW YORK, March 12... More...>>
03/04/20147:05AMGLOBENCCN Updates Guidelines for Hereditary Colon Cancer Testing
SALT LAKE CITY, March 4, 2014 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today is pleased to note that the National Comprehensive Cancer Network (NCCN) has revised its medical guidelines to expand Lynch syndrome screening. Lynch syndrome is the most common cause of hereditary colon cancer in adults. Myriad... More...>>
03/03/20147:00AMGLOBEMyriad Publishes Clinical Utility Study for Prolaris(R)
SALT LAKE CITY, March 3, 2014 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced that it has published data from the PROCEDE 500 study in the journal Current Medical Research and Opinion, demonstrating that 65 percent of physicians changed their original treatment plans for men with prostate cancer... More...>>
02/19/20142:50PMZACKSMyriad Genetics Unveils Prolaris Data - Analyst Blog
Shares of Myriad Genetics Inc. (MYGN) surged 11.4% at yesterday’s market close following the company’s recent release of positive data on its Prolaris test – a 46-gene molecular diagnostic test – in the Journal of Urology. The Prolaris test correctly predicted those prostrate cancer patients who... More...>>
02/18/20147:05AMGLOBEMyriad Genetics Publishes Prolaris(R) Data in the Journal of Urology
SALT LAKE CITY, Feb. 18, 2014 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced it has published data in the Journal of Urology demonstrating that its Prolaris test accurately predicted, based on biopsy specimens, which men would develop biochemical recurrence (BCR) or metastatic disease following... More...>>
02/07/20147:00AMGLOBEBRCA Patent Owners and Gene by Gene, Ltd. Resolve Patent Suit
HOUSTON and SALT LAKE CITY, Feb. 7, 2014 (GLOBE NEWSWIRE) -- Gene by Gene, Ltd. and Myriad Genetics, Inc., the University of Utah Research Foundation, HSC Research and Development Limited Partnership, Endorecherche, Inc., and the Trustees of the University of Pennsylvania (the "Patent Owners") have reached an agreement... More...>>
02/05/20144:47PMDJNMARKET SNAPSHOT: U.S. Stocks Fall; Data Stoke Fears Of Slowdown
By Anora Mahmudova, MarketWatch NEW YORK (MarketWatch) -- U.S. stocks ended Wednesday's choppy session lower as investors were unable to shrug off worries over the economy. A weaker-than-expected ADP jobs report and the ISM report on the services side of the economy compounded fears that the U.S. recovery is still vulnerable... More...>>
02/05/20142:11PMDJNMARKET SNAPSHOT: U.S. Stocks Eye Rebound; Dow Reverses Losses
By Anora Mahmudova, MarketWatch NEW YORK (MarketWatch) -- U.S. stocks rebounded from their session lows, with the Dow Jones Industrial Average breaking into positive territory, as investors digested the ISM services-sector survey and private-sector jobs report from ADP. After recent selling on Wall Street the main indexes... More...>>


NYSE and AMEX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

1 site:2 us nasdaq mygn140425 01:38